PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY-Reference-Cited by-同舟云学术

PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Published:2018-07 Issue:7 Volume:38 Page:1276-1288
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Christenbury Joseph G.,Phasukkijwatana Nopasak,Gilani Fatimah,Freund K. Bailey,Sadda SriniVas,Sarraf David

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference35 articles.

1. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study;Brown;Ophthalmology,2009

2. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;NEJM,2006

3. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration;Heier;Ophthalmology,2006

4. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP);Rofagha;Ophthalmology,2013

5. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials;Grunwald;Ophthalmology,2015

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes;Ophthalmic Research;2024-04-15

2. MULTIMODAL IMAGING IN NONEXUDATIVE CHOROIDAL NEOVASCULARIZATION;Retina;2023-11

3. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up);Graefe's Archive for Clinical and Experimental Ophthalmology;2023-10-21

4. Multimodal Imaging of Quiescent Choroidal Neovascularization: Status of Retinal Pigment Epithelium;Ophthalmology in Russia;2023-04-06

5. Maximal Extension Interval and Visual Outcomes in a Treat-and-Extend Protocol: A Post Hoc Analysis of the CANTREAT Randomized Trial;Ophthalmologica;2023